Optimization of Clozapine Treatment
Authors:
- Ismael OlmosIOIsmael Olmos
- Carina RicciardiCRCarina Ricciardi
- Mauricio MatoMMMauricio Mato
- Natalia GuevaraNGNatalia Guevara
- Cecilia MaldonadoCMCecilia Maldonado
- Marta VázquezMVMarta Vázquez
- Mauricio Md ToledoMTMauricio Md Toledo
- Valentina Msc BlancoVBValentina Msc Blanco
- José L. BadanoJBJosé L. Badano
- Alfonso CayotaACAlfonso Cayota
- 22 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 45 (1) , 20-27
Abstract
Purpose/Background: Clozapine is the recommended drug for treatment-resistant schizophrenia. Drug response could be affected by numerous factors such as age, sex, body mass index, co-medication, consumption of xanthine-containing beverages, smoking, and genetic variants of the enzymes involved in clozapine metabolism (CYP1A2, CYP3A4, and, to a lesser extent, CYP2C19 and CYP2D6). This study evaluated genetic and nongenetic variables that may affect clozapine plasma concentrations in Uruguayan patients with schizophrenia. Methods/Procedures: Demographic data including sex, age, ethnicity, body weight, smoking habit, concomitant medication, and xanthine consumption were collected through a data collection form. Clozapine and norclozapine concentrations were determined using an HPLC system equipped with a UV detector. Genetic variants were determined through next-generation sequencing using Illumina sequencing technology and a panel of DNA probes. Findings/Results: Fifty patients were included in the study. After evaluation, only tobacco use and obesity had a significant impact on clozapine exposure (P < 0.05). The high prevalence of the genetic variant CYP1A2*1F may account for the significant impact that tobacco smoking has on clozapine concentrations. Some common adverse effects observed in this study depend on clozapine plasma concentrations, such as constipation and sialorrhea. Implications/Conclusions: These types of studies provide the clinician with tools to optimize clozapine therapy, attempting to use the minimum effective dose and attenuating the burden of concentration-dependent adverse reactions.Keywords
This publication has 43 references indexed in Scilit:
- Prevention of suicide by clozapine in mental disorders: systematic reviewEuropean Neuropsychopharmacology, 2023
- A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant SchizophreniaCNS Drugs, 2022
- The nature of schizophrenia: As broad as it is longSchizophrenia Research, 2022
- The clinical significance of duration of untreated psychosis: an umbrella review and random‐effects meta‐analysisWorld Psychiatry, 2021
- Elevated Clozapine Concentrations in Clozapine-Treated Patients with HypersalivationClinical Pharmacokinetics, 2020
- Schizophrenia—An OverviewJAMA Psychiatry, 2020
- The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic reviewPsychopharmacology, 2015
- Drug interactions affecting clozapine levelsJournal of Psychiatric Intensive Care, 2013
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Nuevas guías para el uso de la polifarmacia antipsicóticaRevista de Psiquiatría y Salud Mental, 2013